Ting Pau Oei is an accomplished healthcare professional with a 20 year track record of successful healthcare investing.  His career is unique, having been a partner at both a strategic corporate and independent venture capital firm.  He has invested in over 60 life sciences companies, served on the board of directors of over 25 private venture backed companies, many of whom have been acquired or gone public.  In addition to his extensive venture capital investing experience, Mr. Oei has broad prior experience as an operating executive including business development, M&A, marketing & sales. He has extensive international experience having worked and lived abroad for many years.

Currently, Mr. Oei is Managing Partner of Fox Feather Ventures LLC, a venture capital advisory and investment firm he founded in 2012.  Under Mr. Oei’s leadership, Fox Feather Ventures LLC has been instrumental in the formation of several start-up life sciences companies including Otomagentics LLC, a spinout from the University of Maryland, where Mr. Oei is the Board Chairman, and xMD Diagnostics LLC, a diagnostics company whose technology is licensed from the NIH.  Previously, Mr. Oei was a founding Partner of L Capital Partners SBIC, LP, a New York City based, $165 million, diversified venture capital fund, where he headed the healthcare practice.

Prior to joining L Capital Partners in 2004, Mr. Oei spent a total of 22 years at Johnson & Johnson, the last 12 years as Vice President at Johnson & Johnson Development Corporation (JJDC), J&J’s longstanding venture capital arm.  He was responsible for the firm’s biotech, diagnostics and healthcare information technology investments which included a broad range of companies from early-stage startups to developmental/growth stage and public companies, including Shire Pharmaceuticals Group plc (IPO), Barrier Therapeutics Inc. (IPO), Protez Pharmaceuticals (Chairman, acquired by Novartis), Acorda Therapeutics (IPO), COR Therapeutics Inc. (acquired by Millenium), Rigel Pharmaceuticals (IPO), Allos Therapeutics Inc. (IPO), Bluebird Therapeutics (IPO) and Neurocrine Biosciences Inc. (IPO), among others.

Prior to joining Johnson & Johnson, Mr. Oei held positions at Abbott Laboratories, Merck & Co., and American Cyanamid.

Mr. Oei is a past Member of BIO’s Emerging Company Investor Forum’s Advisory Board and the Rutgers Innovation Advisory Board. He currently serves on the Board of Directors of xMD Diagnostics LLC and WellTrackOne LLC.

Mr. Oei received an M.B.A. from Columbia Business School at Columbia University and a B.A. in Economics from Union College, New York.